厄洛替尼联合抗血管生成药物对比厄洛替尼单药一线治疗EGFR突变晚期非小细胞肺癌的疗效  

The Efficacy of Erlotinib Combined with Anti-Angiogenesis Treatment in Comparison with Erlotinib Alone as First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer

作　　者：冯卫能[1] 邓秋梅 FENG Wei-neng;DENG Qiu-mei(Department of Head and Neck/Thoracic Oncology,The First People's Hospital of Foshan,Guangdong Foshan 528000,China;不详)

机构地区：[1]佛山市第一人民医院头颈胸肿瘤内科,广东佛山528000 [2]广东省人民医院肿瘤中心,广东省医学科学院,广东省肺癌研究所,广东省心血管病研究所,广州510080

出　　处：《循证医学》2020年第1期53-57,共5页The Journal of Evidence-Based Medicine

摘　　要：1文献来源研究一:Nakagawa K,Garon EB,Seto T,et al.Ramucirumab plus Erlotinib in patients with untreated,EGFR-mutated,advanced non-small-cell lung cancer(RELAY):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2019,20(12):1655-1669.研究二:Zhou Q,Wu YL,Cheng Y,et al.CTONG 1509:Phase 3 study of Erlotinib with or without Bevacizumab in untreated Chinese patients with advanced EGFR-mutated NSCLC[J].Ann Oncol,2019,30(5S):v602-v660.2证据水平1b。3背景临床前和临床研究证实厄洛替尼联合抗血管生成药物具有协同作用,可显著延长表皮生长因子受体(epidermal growth factor receptor,EGFR)敏感突变晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的无进展生存期(progression-free survival,PFS)。

关 键 词：非小细胞肺癌 EGFR敏感突变 EGFR-TKI联合抗血管生成 

分 类 号：R734.2[医药卫生—肿瘤]